Table 3.
Association between neoadjuvant treatment strategies with perioperative and histopathologic outcomes on adjusted multivariable regression models.
| Unmatched | Matched | |
|---|---|---|
|
|
||
| Odds Ratio (95% Confidence Interval) | ||
|
|
||
| Perioperative Outcomes | ||
| 30-day Readmission a | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.18 (0.89-1.55) | 1.21 (0.90-1.62) |
| 30-day Mortality a | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.01 (0.69-1.48) | 1.17 (0.75-1.82) |
| 90-day Mortality a | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.16 (0.89-1.52) | 1.05 (0.78-1.40) |
| Length of Stay a,b | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.10 (1.04-1.17) | 1.09 (1.03-1.16) |
|
| ||
| Histopathologic Outcomes | ||
| Pathologic Complete Response a | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.58 (1.28-1.93) | 1.48 (1.19-1.85) |
| Negative Margins a | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.62 (1.24-2.12) | 1.74 (1.29-2.35) |
| Negative Pathologic Lymph Nodes a | ||
| Neoadjuvant Treatment | ||
| Chemotherapy | 1.00 (REF) | 1.00 (REF) |
| Chemoradiation | 1.38 (1.21-1.58) | 1.32 (1.13-1.54) |
a
Each outcome modeled separately, adjusting for gender, age, race, insurance status, facility type, Charlson/Deyo score, tumor location, tumor differentiation, lymphovascular invasion, tumor size, clinical T-category, and clinical N-category. Reference category for each model is neoadjuvant chemotherapy.
b
Length of stay was modeled as a multivariable Poisson regression with results reported as incidence-rate ratios and 95% confidence intervals.